Alicia Gonzalez-Martinez

Dr. Alicia Gonzalez-Martinez

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 April 2020 in The Journal of Headache and Pain
Verified
Journal Article
Open access
PDF file
O(On behalf of School of Advanced Studies of European Headache Federation (EHF-SAS)
On behalf of School of Advanced Studies of European Headache Federation (EHF-SAS)
MTM. Torres-Ferrús
M. Torres-Ferrús
FUF. Ursitti
F. Ursitti
AAA. Alpuente
A. Alpuente
FBF. Brunello
F. Brunello
CLC. Lampl
C. Lampl
Chronic migraine is a neurological disorder characterized by 15 or more headache days per month of which at least 8 days show typical migraine features. The process that describes the development from episodic migraine into chronic migraine is commonly referred to as migraine transformation or chronification. Ample studies have attempted to identify factors associated with migraine transformation from different perspectives. Understanding CM as a pathological brain state with trigeminovascular participation where biological changes occur, we have completed a comprehensive review on the clinical, epidemiological, genetic, molecular, structural, functional, physiological and preclinical evidence available.

15 February 2022 in Cephalalgia
Verified
Journal Article
Closed access
DGDavid García-Azorín
David García-Azorín
ALAlmudena Layos-Romero
Almudena Layos-Romero
Jesus Porta EtessamJesus Porta Etessam
Jesus Porta Etessam
JMJavier A Membrilla
Javier A Membrilla
ECEdoardo Caronna
Edoardo Caronna
PPPatricia Pozo-Rosich
Patricia Pozo-Rosich
Background: Headache is a frequent symptoms of coronavirus disease 2019 (COVID-19). Its long-term evolution remains unknown. We aim to evaluate the long-term duration of headache in patients that presented headache during the acute phase of COVID-19. Methods: This is a post-hoc multicenter ambisective study including patients from six different third-level hospitals between 1 March and 27 April 2020. Patients completed 9 months of neurological follow-up. Results: We included 905 patients. Their median age was 51 (IQR 45–65), 66.5% were female, and 52.7% had a prior history of primary headache. The median duration of headache was 14 (6–39) days; however, the headache persisted after 3 months in 19.0% (95% CI: 16.5–21.8%) and after 9 months in 16.0% (95% confidence interval: 13.7–18.7%). Headache intensity during the acute phase was associated with a more prolonged duration of headache (Hazard ratio 0.655; 95% confidence interval: 0.582–0.737). Conclusion: The median duration of headache was 2 weeks, but in approximately a fifth of patients it became persistent and followed a chronic daily pattern.

22 June 2022 in Seizure: European Journal of Epilepsy
Verified
Journal Article
Closed access
AAAngel Aledo-Serrano
Angel Aledo-Serrano
RHRoshan Hariramani
Roshan Hariramani
AGAlicia Gonzalez-Martinez
Alicia Gonzalez-Martinez
JÁJorge Álvarez-Troncoso
Jorge Álvarez-Troncoso
RTRafael Toledano
Rafael Toledano
AGAntonio Gil-Nagel
Antonio Gil-Nagel

8 January 2021 in European Journal of Neurology
Verified
Journal Article
Open access
PDF file
AGAlicia Gonzalez-Martinez
Alicia Gonzalez-Martinez
VFVíctor Fanjul
Víctor Fanjul
CRCarmen Ramos
Carmen Ramos
JBJorge Serrano Ballesteros
Jorge Serrano Ballesteros
MBMarta Bustamante
Marta Bustamante
AGAna Beatriz Gago-Veiga
Ana Beatriz Gago-Veiga
Background and purpose: Headache is an important manifestation during SARS‐CoV‐2 infection. In this study, the aim was to identify factors associated with headache in COVID‐19 and headache characteristics.Methods: This case–control study includes COVID‐19 hospitalized patients with pneumonia during March 2020. Controls comprise COVID‐19 patients without headache and the cases are COVID‐19 patients with headache. Demographic, clinical and laboratory data were obtained from the medical records. Headache characteristics were evaluated by semi‐structured telephonic interview after discharge.Results: Of a total of 379 COVID‐19 patients, 48 (13%) developed headache. Amongst these, 30 (62%) were men and the median age was 57.9 (47–73) years. Headache was associated with younger age, fewer comorbidities and reduced mortality, as well as with low levels of C‐reactive protein, mild acute respiratory distress syndrome and oropharyngeal symptoms. A logistic multiple regression model revealed that headache was directly associated with D‐dimer and creatinine levels, the use of high flow nasal cannula and arthromyalgia, whilst urea levels, beta‐lactamic treatment and hypertension were negatively associated with headache. COVID‐19‐associated headache characteristics were available for 23/48 (48%) patients. Headache was the onset symptom in 8/20 (40%) patients, of mild or moderate intensity in 17/20 (85%) patients, with oppressive characteristics in 17/18 (94%) and of holocranial 8/19 (42%) or temporal 7/19 (37%) localization.Conclusions: Our results show that headache is associated with a more benign SARS‐CoV‐2 infection. COVID‐19‐associated headache appears as an early symptom and as a novel headache with characteristics of headache attributed to systemic viral infection. Further research addressing the underlying mechanisms to confirm these findings is warranted.

12 July 2022 in European Journal of Neurology
Verified
Journal Article
Closed access
AGAlicia Gonzalez-Martinez
Alicia Gonzalez-Martinez
JPJosué Pagán
Josué Pagán
ASAncor Sanz-Garcia
Ancor Sanz-Garcia
DGDavid García-Azorín
David García-Azorín
JRJaime Samuel Rodríguez‐Vico
Jaime Samuel Rodríguez‐Vico
AGAna Beatriz Gago-Veiga
Ana Beatriz Gago-Veiga

23 October 2017 in Neurological Research
Verified
Journal Article
Closed access
JPJesús Piqueras-Flores
Jesús Piqueras-Flores
ALAna López-García
Ana López-García
ÁMÁlvaro Moreno-Reig
Álvaro Moreno-Reig
AGAlicia Gonzalez-Martinez
Alicia Gonzalez-Martinez
AHAmalia Hernández-González
Amalia Hernández-González
AJAlfonso Jurado-Román
Alfonso Jurado-Román
Parkinson's disease (PD) patients have most frequently heart failure. The cause of this increased prevalence is not known. We designed a study to assess the cardiac function and cardiac structure in patients with PD compared to a control group. Cross-sectional study with 50 PD patients and 50 healthy matched controls. We performed electro and echocardiograms to all patients and controls. The measurements were blind. In addition, we performed a neurological assessment. PD patients had higher left ventricular mass index (114.2 ± 38.4 vs. 94.1 ± 26.4 g/m2; P = 0.003) and higher left atrial volume (30.1 ± 7.9 vs. 26.7 ± 6.2 ml/m2; P = 0.01). PD was an independent risk factor for elevated left ventricular filling pressures (OR = 2.7, CI 95% 2.2-6.3; P = 0.004). Concentric remodeling and left ventricular hypertrophy were associated with more advanced Hoehn and Yahr stages. Moreover, patients with more dysautonomia symptoms showed more left ventricular hypertrophy. Finally, PD group had longer QT interval than control group regardless of the drugs. PD is significantly associated with increased concentric left ventricular hypertrophy and diastolic dysfunction. Advanced stages of PD are associated with a more severe cardiac affection. These findings can explain the increase of heart failure in PD patients. Cardiomyopathy could be a non-motor parkinsonian symptom.